Protocol Ledger

NCT03199885 · Phase III · TERMINATED

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Interventional Phase III clinical trial protocol NCT03199885 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-04-05 Enrollment: 190 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03199885
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)190 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03199885
Protocol FieldVerified Registry Value
NCT IdentifierNCT03199885
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment190 participants (ACTUAL)
Registered Start Date2019-04-05
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI